- Location
ACS Patients
"-
Bayer HealthCare Has Failed to Win The Backing of The US FDA's Cardiovascular
Jan 20, 2014Bayer HealthCare has failed to win the backing of the US FDA's Cardiovascular and Renal Drugs Advisory Committee to expand the use of its oral anticoagulant Xarelto (rivaroxaban) 2.5 mg twice daily (BID) in combination with standard ...
Tags: FDA Panel, ACS Patients
-
Cerenis Therapeutics Did Not Reach Its Primary Endpoint in Post-ACS Patients
Jan 3, 2014Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression) study did not reach its primary endpoint in post-Acute Coronary Syndrome ...
Tags: Cerenis Therapeutics, Phase IIb CHI-SQUARE, post-Acute Coronary Syndrome